Sumitomo Dainippon Pharma Co LtdSumitomo Dainippon Pharma Co Ltd - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This Sustainability assessment for Sumitomo Dainippon Pharma Co Ltd indicates its transparency towards the UN Sustainable Development Goals. The report of Sumitomo Dainippon Pharma Co Ltd is assembled by All Street Sevva using proprietary Cognitive Robots. This webpage contains a zero-cost E,S&G analysis for Sumitomo Dainippon Pharma Co Ltd.

Sumitomo Dainippon Pharma Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.

SDG Transparency Score for Sumitomo Dainippon Pharma Co Ltd 
Low
0 - 3
Medium
4 - 6

8.0

High Impact
7 - 10
Last Score Update: 2023-07-01
What drives the score for Sumitomo Dainippon Pharma Co Ltd 
8.0

Environmental

8.0

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
36Repligen Corp
8.1
High
36Zealand Pharma A/S
8.1
High
55Sumitomo Dainippon Pharma Co Ltd
8.0
High
55Abbott India Ltd
8.0
High
55Amrutanjan Health Care Ltd
8.0
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Sumitomo Dainippon Pharma Co Ltd have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd report the average age of the workforce?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose cybersecurity risks?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd offer flexible work?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd conduct supply chain audits?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose water use targets?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Sumitomo Dainippon Pharma Co Ltd have a product recall in the last two years?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose incidents of discrimination?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Sumitomo Dainippon Pharma Co Ltd issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose parental leave metrics?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Sumitomo Dainippon Pharma Co Ltd involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose its waste policy?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd report according to TCFD requirements?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose energy use targets?

LockedSign up for free to unlock

Does Sumitomo Dainippon Pharma Co Ltd disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Sumitomo Dainippon Pharma Co Ltd have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Sumitomo Dainippon Pharma Co Ltd
These potential risks are based on the size, segment and geographies of the company.

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Sorry!

Failed to process!